2023
DOI: 10.1016/j.jot.2022.10.007
|View full text |Cite
|
Sign up to set email alerts
|

1–2 ​T static magnetic field combined with Ferumoxytol prevent unloading-induced bone loss by regulating iron metabolism in osteoclastogenesis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
9
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 13 publications
(9 citation statements)
references
References 37 publications
0
9
0
Order By: Relevance
“… 14 Furthermore, Zhang et al found that after placing Raw264.7 cells in 1–2 T SMFs for 4 days, the osteoclast formation in the presence of Ferumoxytol was reduced. 15 Kotani et al also found that 8 T high SMF can align both mouse osteoblastic MC3T3-E1 cells and the orientation of bone formation. 16,17 …”
Section: Bone Regenerationmentioning
confidence: 95%
“… 14 Furthermore, Zhang et al found that after placing Raw264.7 cells in 1–2 T SMFs for 4 days, the osteoclast formation in the presence of Ferumoxytol was reduced. 15 Kotani et al also found that 8 T high SMF can align both mouse osteoblastic MC3T3-E1 cells and the orientation of bone formation. 16,17 …”
Section: Bone Regenerationmentioning
confidence: 95%
“…And the osteoclast differentiation was suppressed by decreasing the levels of ROS and blocking NF-κB and MAPK signaling pathways. 159 Chen et al 160 designed a novel nano-fluorescent carbon quantum dots (N-CDs), the results showed the osteoclastogenesis and bone resorption was attenuated via downregulating ROS level by impaired the activation of NF-κB and MAPK pathways. Therefore, NPs can inhibit osteoclast differentiation via the inhibition of MAPK and NF-κB signaling pathways, and decrease the levels of ROS ( Fig.…”
Section: Research Progress On the Interaction Of Nanoparticles With B...mentioning
confidence: 99%
“…Notably, iron oxide nanoparticles (IONs), such as ferumoxytol, approved for iron supplementation in CKD anemia patients will bring additional benefits to anemia patients [ 167 ]. For example, ferumoxytol has been shown to be used in the treatment of other diseases, including leukemia and osteoporosis [ 168 , 169 , 170 ]. Therefore, IONs are expected to be the most promising drugs for the treatment of iron deficiency complicated by osteoporosis.…”
Section: Prevention Of Iron Deficiencymentioning
confidence: 99%